The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile….
Big Announcement Alert: Discoveries meet momentum. Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile....
Taiga Biotechnologies, a clinical-stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease...
Comprised of leaders representing the bioscience industry, University of Colorado, and the City of Aurora, the Board of Directors supports the vision of Fitzsimons Innovation Community.
BioPharma companies have been making some huge strides over the last year with innovations driven by both established players and startups entering the scene. With an impressive 7.32% CAGR and a value of $325.17 billion in 2020 it is a huge industry ripe for growth.
CU SOM professor’s decade of research serves as backbone for improved care guidelines
Colorado’s life sciences ecosystem raised $2.4 billion in 2021, a new record for the fast-growing community that includes companies at all stages of commercialization and academic and research institutions. The 2021 fundraising total is double the $1.2 billion raised by the Colorado life sciences community in 2020. Sources of funding included headline-making IPOs, significant additional capital raised in public markets, an infusion of venture capital, and grants from federal and state sources.
New report demonstrates Community momentum to meet speed-to-market urgency in biotech.
Atara Biotherapeutics announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel®) has been fully validated by the European Medicines Agency (EMA).
Expertscape rankings recognize Richard Schulick, MD, and Marco Del Chiaro, MD, among the top 0.1% of scholars worldwide.
TBX-2400 is expected to improve engraftment and reconstitution of immune system for patients receiving Hematopoietic Stem Cell Transplants.